US FDA warns Pfizer over tardy pharmacovigilance

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2010年 / 1306卷 / 1期

关键词：

Public Health; Legal Action; Chief Executive; Potential Side Effect; Timely Fashion;

D O I：

10.2165/00128415-201013060-00005

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[1] FDA warns Pfizer on sertraline marketing
Barnett, AA
LANCET, 1996, 348 (9025): : 469 - 469
[2] FDA warns Pfizer on failure to report drug problems
Barnett, AA
LANCET, 1996, 347 (9014): : 1546 - 1546
[3] Rituxan associated with PML, warns US FDA
Reactions Weekly, 2007, 1133 (1) : 3 - 3
[4] US FDA warns of hypericum/indinavir interaction
Reactions Weekly, 2000, 789 (1) : 2 - 2
[5] US FDA warns about ibuprofen and aspirin interaction
Reactions Weekly, 2006, 1119 (1) : 2 - 2
[6] US FDA warns against fenfluramine/phentermine combination
Reactions Weekly, 1997, 662 (1) : 2 - 2
[7] Risk of differentiation syndrome with enasidenib, warns US FDA
Reactions Weekly, 2018, 1732 (1) : 4 - 4
[8] US FDA warns of unauthorised devices for diabetes control
Reactions Weekly, 2019, 1755 (1) : 8 - 8
[9] US FDA warns of heart issues, death with clarithromycin
Reactions Weekly, 2018, 1692 (1) : 7 - 7
[10] US FDA warns of increased myopathy risk with Zocor
Reactions Weekly, 2010, 1294 (1) : 1 - 1

← 1 2 3 4 5 →